ISPC iSpecimen Inc. Future Price to Earnings

iSpecimen Inc. generates revenue through commissions from biomaterial transactions via its online marketplace. The business relies on stable demand within the medical sector, which reduces dependence on market cycles. This two-sided digital environment connects biobanks with laboratories, creating a unique network effect. The company's projected P/E multiple on this chart illustrates the valuation trend, where the current status is 0.00.

Price to Expected Earnings Ratio: iSpecimen Inc. (ISPC) for 07/04/2022 - 11/12/2026

Metric breakdowns and analytics for iSpecimen Corp (ISPC)

- stock quotes and analyst forecast:

Stock Price iSpecimen Inc.|ISPC - Analyst Median Target

- market capitalization data:

Market Value iSpecimen Inc|ISPC - Company Buyout Price

- balance sheet equity data:

Net Assets per Single Share iSpecimen|ISPC - Net Asset Value|Market Capitalization to Book Value Ratio ispecimen.com|ISPC - Company Assets

- debt and liquidity details:

- company profitability and valuation multiples indicators:

ISPC - Company Profit|Future Profit iSpecimen Inc.|ISPC - Company Value to Net Income|Forward P/E Multiple iSpecimen Inc.|ISPC - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization iSpecimen Inc|ISPC - Operating profit before amortization|Net earnings per share (EPS TTM) iSpecimen|ISPC - Net earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months ispecimen.com|ISPC - Expected net earnings per share growth this year|Earnings growth forecast for next year iSpecimen Inc.

Basic company analysis:ISPC iSpecimen

The market evaluates the potential of iSpecimen Inc. (ISPC) through the lens of the scalability of its IT marketplace for biospecimen procurement. By analyzing the historical forward P/E ratio of the company on GURU.Markets, an investor can see the ratio of current market capitalization to projected annual earnings, which allows for balancing the risk of overpaying for a technological driver against the probability of capital stagnation amid regulatory changes.

Competitors of iSpecimen Inc.